{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:03:24Z","timestamp":1784311404718,"version":"3.55.0"},"reference-count":89,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000282","name":"Sir Jules Thorn Charitable Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"NIHR Birmingham Biomedical Research Centre","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["NIHR131211"],"award-info":[{"award-number":["NIHR131211"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,6,24]]},"abstract":"<jats:p>This is a consensus guidance document developed by the British Association for the Study of Headache (BASH), of practical recommendations in the use of advanced migraine treatments based on the current literature, guidelines, real-world experience and opinion from an expert consensus group. The target audience for this statement includes all clinical and allied healthcare professionals interested in headache. The introduction of calcitonin gene-related peptide-targeted migraine treatments in addition to botulinum toxin has widened the choice of migraine treatment options. However, there is a lack of consistency in the use and treatment of accessibility across the UK. We have developed a multidisciplinary consensus clinical guidance that makes recommendations on how to use advanced preventative treatments for migraine. The BASH consensus group was composed of consultants, nurses and general practitioners with specialist\u2019s experience in headache. Key clinical questions were agreed by consensus. Each recommendation was based on a selective search of evidence, including meta-analyses, systematic reviews and considered relevant national standards of care. A modified Delphi process was used to obtain consensus on the recommendations via an anonymous voting process by the Consensus Group and BASH Council members. Those not reaching the minimum required consensus level (\u226575%) were amended until agreement was reached or were designated as lacking consensus. Expert practical recommendations on advanced migraine treatments covering common dilemmas are presented. These recommendations aim to optimise patient access and experience of advanced migraine treatments. This document will need to be revised periodically as new evidence emerges.<\/jats:p>","DOI":"10.1136\/jnnp-2026-339062","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:20:19Z","timestamp":1784308819000},"page":"jnnp-2026-339062","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Migraine-advanced preventative treatments: the British Association for the Study of Headache Clinical Practice Recommendations and Consensus Guidance"],"prefix":"10.1136","author":[{"given":"Gina","family":"Kennedy","sequence":"first","affiliation":[{"name":"Department of Neurology, South Tyneside and Sunderland NHS Foundation Trust, South Shields, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3996-8790","authenticated-orcid":false,"given":"David Paul Bartram","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Davies","sequence":"additional","affiliation":[{"name":"Neurology Department, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9495-9006","authenticated-orcid":false,"given":"Anish","family":"Bahra","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Pain Management Centre, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospitals Sussex NHS Foundation Trust, Worthing, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Ghadiri-Sani","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Kamourieh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-4927","authenticated-orcid":false,"given":"Jessie Jie Yi","family":"Gew","sequence":"additional","affiliation":[{"name":"Metabolism and Systems Science, University of Birmingham, Birmingham, UK"},{"name":"Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Long","sequence":"additional","affiliation":[{"name":"IslandHealth, Guernsey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weatherall","sequence":"additional","affiliation":[{"name":"Department of Neurology, Buckinghamshire Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wakerley","sequence":"additional","affiliation":[{"name":"Metabolism and Systems Science, University of Birmingham, Birmingham, UK"},{"name":"Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Anderson","sequence":"additional","affiliation":[{"name":"Neurology Department, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-5132","authenticated-orcid":false,"given":"Alexandra J","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Metabolism and Systems Science, University of Birmingham, Birmingham, UK"},{"name":"Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026071710201249000_jnnp-2026-339062v1.1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1724285"},{"key":"2026071710201249000_jnnp-2026-339062v1.3","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-316074.62","article-title":"Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial","volume":"88","author":"Goadsby","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026071710201249000_jnnp-2026-339062v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"2026071710201249000_jnnp-2026-339062v1.5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Pozo-Rosich","year":"2023","journal-title":"Lancet"},{"key":"2026071710201249000_jnnp-2026-339062v1.6","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735"},{"key":"2026071710201249000_jnnp-2026-339062v1.7","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241252666"},{"key":"2026071710201249000_jnnp-2026-339062v1.8","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"2026071710201249000_jnnp-2026-339062v1.9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"2026071710201249000_jnnp-2026-339062v1.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.988"},{"key":"2026071710201249000_jnnp-2026-339062v1.11","unstructured":"National Institute for Health and Care Excellence . NICE guidance: headaches. 2025 Available: https:\/\/www.nice.org.uk\/guidance\/conditions-and-diseases\/neurological-conditions\/headaches"},{"key":"2026071710201249000_jnnp-2026-339062v1.12","unstructured":"Fischer MA , Jan A . Medication-overuse headache. In: StatPearls. Treasure Island (FL), Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538150\/"},{"key":"2026071710201249000_jnnp-2026-339062v1.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6739.1558"},{"key":"2026071710201249000_jnnp-2026-339062v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210153271601"},{"key":"2026071710201249000_jnnp-2026-339062v1.15","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415593088"},{"key":"2026071710201249000_jnnp-2026-339062v1.16","doi-asserted-by":"crossref","first-page":"3331024231156922","DOI":"10.1177\/03331024231156922","article-title":"Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis","volume":"43","author":"Giri","year":"2023","journal-title":"Cephalalgia"},{"key":"2026071710201249000_jnnp-2026-339062v1.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01711.x"},{"key":"2026071710201249000_jnnp-2026-339062v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01190.x"},{"key":"2026071710201249000_jnnp-2026-339062v1.19","first-page":"335","article-title":"Paradoxical effects of frequent analgesic use","volume":"33","author":"Kudrow","year":"1982","journal-title":"Adv Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01859.x"},{"key":"2026071710201249000_jnnp-2026-339062v1.21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/brain\/awz052","article-title":"Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial","volume":"142","author":"Pijpers","year":"2019","journal-title":"Brain"},{"key":"2026071710201249000_jnnp-2026-339062v1.22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1453183","article-title":"Efficacy and safety of onabotulinumtoxinA in the treatment of medication overuse headache: a systematic review","volume":"15","author":"Lang","year":"2024","journal-title":"Front Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.23","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur J Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ane.13472","article-title":"Refractory migraine profile in CGRP-monoclonal antibodies scenario","volume":"144","author":"Silvestro","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"2026071710201249000_jnnp-2026-339062v1.25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s10194-024-01813-3","article-title":"Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis","volume":"25","author":"Scheffler","year":"2024","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.26","doi-asserted-by":"crossref","first-page":"109205","DOI":"10.1016\/j.clineuro.2025.109205","article-title":"Medication-overuse headache: Bridging therapies for detoxification","volume":"259","author":"Wakerley","year":"2025","journal-title":"Clin Neurol Neurosurg"},{"key":"2026071710201249000_jnnp-2026-339062v1.27","unstructured":"SIGN . Pharmacological management of migraine. 2023. Available: https:\/\/www.sign.ac.uk\/guidelines\/pharmacological-management-of-migraine\/"},{"key":"2026071710201249000_jnnp-2026-339062v1.28","unstructured":"Scottish Medicines Consortium . Erenumab (Aimovig): full submission (SMC2134). 2021. Available: https:\/\/scottishmedicines.org.uk\/medicines-advice\/erenumab-aimovig-full-submission-smc2134\/"},{"key":"2026071710201249000_jnnp-2026-339062v1.29","doi-asserted-by":"crossref","unstructured":"Pozo-Rosich P , Caronna E , Sacco S , et al . Early treatment in migraine \u2013 A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society. Cephalalgia 2025;45. doi:10.1177\/03331024251387721","DOI":"10.1177\/03331024251387721"},{"key":"2026071710201249000_jnnp-2026-339062v1.30","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364676"},{"key":"2026071710201249000_jnnp-2026-339062v1.31","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364677"},{"key":"2026071710201249000_jnnp-2026-339062v1.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"2026071710201249000_jnnp-2026-339062v1.33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40120-023-00562-w","article-title":"Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial","volume":"13","author":"Schwedt","year":"2024","journal-title":"Neurol Ther"},{"key":"2026071710201249000_jnnp-2026-339062v1.34","doi-asserted-by":"crossref","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","article-title":"Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system","volume":"14","author":"Sun","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026071710201249000_jnnp-2026-339062v1.35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1431562","article-title":"Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026071710201249000_jnnp-2026-339062v1.36","doi-asserted-by":"crossref","first-page":"3331024231159366","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"2026071710201249000_jnnp-2026-339062v1.37","unstructured":"AbbVie Ltd . Aquipta 60 mg tablets [summary of product characteristics]. 2025. Available: https:\/\/www.medicines.org.uk\/emc\/product\/15049\/smpc#gref"},{"key":"2026071710201249000_jnnp-2026-339062v1.38","unstructured":"Pfizer Limited . Vydura 75 mg oral lyophilisate [Summary of product characteristics]. 2026. Available: https:\/\/www.medicines.org.uk\/emc\/product\/13928\/smpc"},{"key":"2026071710201249000_jnnp-2026-339062v1.39","doi-asserted-by":"crossref","first-page":"3331024241299753","DOI":"10.1177\/03331024241299753","article-title":"Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis","volume":"44","author":"Peterlin","year":"2024","journal-title":"Cephalalgia"},{"key":"2026071710201249000_jnnp-2026-339062v1.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"2026071710201249000_jnnp-2026-339062v1.41","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.42","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s13311-023-01394-0","article-title":"Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis","volume":"20","author":"Lambru","year":"2023","journal-title":"Neurotherapeutics"},{"key":"2026071710201249000_jnnp-2026-339062v1.43","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211048765"},{"key":"2026071710201249000_jnnp-2026-339062v1.44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000518899","article-title":"Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series","volume":"85","author":"Patier Ruiz","year":"2022","journal-title":"Eur Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/neurolint16010019","article-title":"Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study","volume":"16","author":"Suliman","year":"2024","journal-title":"Neurol Int"},{"key":"2026071710201249000_jnnp-2026-339062v1.46","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine","volume":"22","author":"Cohen","year":"2021","journal-title":"Pain Med"},{"key":"2026071710201249000_jnnp-2026-339062v1.47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain Ther"},{"key":"2026071710201249000_jnnp-2026-339062v1.48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40263-024-01086-z","article-title":"Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review","volume":"38","author":"Salim","year":"2024","journal-title":"CNS Drugs"},{"key":"2026071710201249000_jnnp-2026-339062v1.49","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14080529","article-title":"Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine","volume":"14","author":"Scuteri","year":"2022","journal-title":"Toxins (Basel)"},{"key":"2026071710201249000_jnnp-2026-339062v1.50","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14120847","article-title":"OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine","volume":"14","author":"Argyriou","year":"2022","journal-title":"Toxins (Basel)"},{"key":"2026071710201249000_jnnp-2026-339062v1.51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/head.14244","article-title":"Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine","volume":"62","author":"Ailani","year":"2022","journal-title":"Headache"},{"key":"2026071710201249000_jnnp-2026-339062v1.52","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420970507"},{"key":"2026071710201249000_jnnp-2026-339062v1.53","doi-asserted-by":"crossref","unstructured":"Iannone LF , Romozzi M , Russo A , et al . Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study). Cephalalgia 2025;45. doi:10.1177\/03331024251398011","DOI":"10.1177\/03331024251398011"},{"key":"2026071710201249000_jnnp-2026-339062v1.54","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40122-024-00649-8","article-title":"Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review","volume":"13","author":"Blumenfeld","year":"2024","journal-title":"Pain Ther"},{"key":"2026071710201249000_jnnp-2026-339062v1.55","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/head.14095","article-title":"Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study","volume":"61","author":"Jakate","year":"2021","journal-title":"Headache"},{"key":"2026071710201249000_jnnp-2026-339062v1.56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","article-title":"Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study","volume":"13","author":"Alsaadi","year":"2024","journal-title":"Neurol Ther"},{"key":"2026071710201249000_jnnp-2026-339062v1.57","doi-asserted-by":"crossref","first-page":"3331024241297673","DOI":"10.1177\/03331024241297673","article-title":"Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications","volume":"45","author":"van der Arend","year":"2025","journal-title":"Cephalalgia"},{"key":"2026071710201249000_jnnp-2026-339062v1.58","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: A new safety risk for patients treated with erenumab","volume":"61","author":"Saely","year":"2021","journal-title":"Headache"},{"key":"2026071710201249000_jnnp-2026-339062v1.59","doi-asserted-by":"crossref","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","article-title":"Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study","volume":"99","author":"de Vries Lentsch","year":"2022","journal-title":"Neurology"},{"key":"2026071710201249000_jnnp-2026-339062v1.60","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01640-y"},{"key":"2026071710201249000_jnnp-2026-339062v1.61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/head.14679","article-title":"Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience","volume":"64","author":"Chhabra","year":"2024","journal-title":"Headache"},{"key":"2026071710201249000_jnnp-2026-339062v1.62","doi-asserted-by":"crossref","first-page":"1387044","DOI":"10.3389\/fneur.2024.1387044","article-title":"Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine","volume":"15","author":"Van Der Arend","year":"2024","journal-title":"Front Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.63","unstructured":"MedShadow Foundation . FDA side effects update: migraine drugs and high blood pressure and circulation problems."},{"key":"2026071710201249000_jnnp-2026-339062v1.64","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25831"},{"key":"2026071710201249000_jnnp-2026-339062v1.65","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213852","article-title":"CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review","volume":"105","author":"Eller","year":"2025","journal-title":"Neurology"},{"key":"2026071710201249000_jnnp-2026-339062v1.66","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaneurol.2024.4537","article-title":"Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine","volume":"82","author":"Yang","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.67","doi-asserted-by":"crossref","first-page":"104286","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","article-title":"Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report","volume":"28","author":"Aradi","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026071710201249000_jnnp-2026-339062v1.68","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/03331024211037277","article-title":"Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention","volume":"42","author":"Rozen","year":"2022","journal-title":"Cephalalgia"},{"key":"2026071710201249000_jnnp-2026-339062v1.69","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.70","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"G\u00e9rard","year":"2022","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon","volume":"4","author":"Breen","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026071710201249000_jnnp-2026-339062v1.72","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.820006","article-title":"Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide\u2019s Motor-Stimulating and Prosecretory Function in the Intestine","volume":"12","author":"Holzer","year":"2021","journal-title":"Front Physiol"},{"key":"2026071710201249000_jnnp-2026-339062v1.73","unstructured":"Health and Safety Executive . Latex allergies. n.d. Available: https:\/\/www.hse.gov.uk\/skin\/employ\/latex.htm"},{"key":"2026071710201249000_jnnp-2026-339062v1.74","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40266-020-00776-9","article-title":"Recent Advances in the Management of Migraine in Older Patients","volume":"37","author":"Soni","year":"2020","journal-title":"Drugs Aging"},{"key":"2026071710201249000_jnnp-2026-339062v1.75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14656566.2018.1543660","article-title":"How do you choose the appropriate migraine pharmacotherapy for an elderly person?","volume":"20","author":"Curto","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2026071710201249000_jnnp-2026-339062v1.76","doi-asserted-by":"crossref","DOI":"10.1007\/s11916-019-0789-6","article-title":"Traditional and Novel Migraine Therapy in the Aging Population","volume":"23","author":"Mathew","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"2026071710201249000_jnnp-2026-339062v1.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"2026071710201249000_jnnp-2026-339062v1.78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/03331024221076485","article-title":"Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies","volume":"42","author":"Diener","year":"2022","journal-title":"Cephalalgia"},{"key":"2026071710201249000_jnnp-2026-339062v1.79","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.80","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients","volume":"24","author":"Mu\u00f1oz-Vendrell","year":"2023","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.81","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"2026071710201249000_jnnp-2026-339062v1.82","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01148-9","article-title":"Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials","volume":"21","author":"Stauffer","year":"2020","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.83","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","article-title":"Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial","volume":"38","author":"Reuter","year":"2021","journal-title":"Adv Ther"},{"key":"2026071710201249000_jnnp-2026-339062v1.84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","article-title":"Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials","volume":"23","author":"Lampl","year":"2022","journal-title":"J Headache Pain"},{"key":"2026071710201249000_jnnp-2026-339062v1.85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"2026071710201249000_jnnp-2026-339062v1.86","doi-asserted-by":"crossref","unstructured":"Ivans A , Stringfellow J , Coric V , et al . Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study (2101). Neurology 2020;94. doi:10.1212\/WNL.94.15_supplement.2101","DOI":"10.1212\/WNL.94.15_supplement.2101"},{"key":"2026071710201249000_jnnp-2026-339062v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2020.02.017"},{"key":"2026071710201249000_jnnp-2026-339062v1.88","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00415-022-11457-5","article-title":"OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study","volume":"270","author":"Altamura","year":"2023","journal-title":"J Neurol"},{"key":"2026071710201249000_jnnp-2026-339062v1.89","doi-asserted-by":"crossref","first-page":"107611","DOI":"10.1016\/j.clineuro.2023.107611","article-title":"Effectiveness and safety of CGRP monoclonal antibodies in migraine related to mitochondrial diseases in patients with NARP and PEO syndromes","volume":"226","author":"Silvestro","year":"2023","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2026-339062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:20:33Z","timestamp":1784308833000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2026-339062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":89,"alternative-id":["10.1136\/jnnp-2026-339062"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2026-339062","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}